• Research projects using MAbSilico AI-driven tools

    Methods to Determine Interaction Interfaces Between β-Arrestins and Their Protein Partners

    #Protein complex; #β-arrestin partners; #Interface region; #Protein–protein docking

    We present here a method in two steps: protein–protein docking allows finding a limited number of peptides predicted to be involved in the interaction, and then experimental approaches that might be used for validating the prediction.


    Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

    #TNBC; #Human antibody-based therapy; #Immunomodulation; #Protease; #Tumor microenvironment; #Phage display

    This study explores whether cath-D is a tumor cell-associated extracellular biomarker and a potent target for antibody-based therapy in TNBC.

    Journal for ImmunoTherapy of Cancer, Feb 2019

    A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions

    #Transferrin receptor 1; #iron metabolism; #leukemia; #therapeutic antibody

    Targeting TfR1 using the fully human anti-TfR1 H7 is a promising tool for the treatment of leukemia and lymphoma.

    mAbs, Feb 2019

    G protein–dependent signaling triggers a β-arrestin–scaffolded p70S6K/ rpS6 module that controls 5′TOP mRNA translation

    #GPCR; #FSHR; #gene regulation

    This work highlights new relationships between G proteins and β-arrestins when acting cooperatively on a common signaling pathway, contrasting with their previously shown parallel action on the ERK MAP kinase pathway. In addition, this study provides insights into how GPCR can exert trophic effects in the cell.

    FASEB Journal,

    5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies


    #heparin; #monoclonal antibody; #platelet activation; #thrombocytopenia

    5B9 is the first anti‐PF4/H monoclonal antibody with a human Fc fragment, which induces similar cellular activation as HIT antibodies. Moreover, 5B9 binds epitopes within PF4 that are likely to be critical for the pathogenicity of HIT antibodies.

    Journal of thrombosis and haemostasis, Aug 2017

    Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges

    #Antibody; #biopharmaceuticals; #GPCR; #G protein; #nanobody; #phage display; #β-arrestin

    The conference ended with the consensus that Abs and especially Nbs are opening a new era of research on GPCR structure, pharmacology and pathophysiology.

    mAbs, Jun 2017

    Eculizumab epitope on complement C5: Progress towards a better understanding of the mechanism of action

    #Eculizumab; #Complement C5; #Molecular docking; #Conformational epitope; #Mechanism of action; #Therapeutic antibody

    Sequence analysis, in silico docking and reverse phase protein array were implemented to fully characterize the eculizumab epitope on human complement C5.

    Molecular Immunology, Sep 2016